Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Posts
- Category: Articles (continued)
- Two Proteins Offer a “Clearer” Way to Treat Huntington’s Disease
- Two-birds-one-stone strategy shows promise in RNA-repeat expansion diseases
- UBC scientists develop test to measure effectiveness of treatments for Huntington’s disease
- UC San Diego Health System Named Center of Excellence for Huntington’s Disease
- Uguale, ma diversa: la Malattia di Huntington Giovanile -
- UI neuroscientists receive major grant to continue work on Huntington’s disease (HD)
- Un voto, 100.000 aiuti concreti – Summer Edition
- UniQure
- uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
- uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington's disease
- uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach
- uniQure licenses RNA interference technology to advance Huntington’s disease program
- uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference
- uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
- uniQure Presents New Preclinical Data on AMT-130 in Huntington's Disease at CHDI's 12th Annual Huntington's Disease Therapeutics Conference
- uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at the ESGCT 25th Anniversary Congress in Berlin
- uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
- Unmet Medical Needs Drive the Global Huntington’s Disease Therapeutics Market, According to New Report by Global Industry Analysts, Inc.
- Unraveling the mysteries of the mitochondria in Huntington’s disease – and getting fast, clear, and useful results from research studies
- Update on molecular therapies for Huntington’s disease
- Using exercise to reduce glutamate build-up in the brain
- Utah Chemists Use Nanopores to Detect DNA Damage
- Vaccinex Inc. Completes Enrollment of Cohort A in its SIGNAL Clinical Trial, a Randomized Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503 in Subjects at Risk for or with Early Signs of Huntington’s Disease
- Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease
- Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease
- Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
- Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
- Voyager Therapeutics & Genzyme Announce Major Strategic Collaboration to Develop and Commercialize Novel AAV Gene Therapies for Patients with CNS Disorders
- Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
- Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
- Vybion Huntington's Disease Drug Patent receives Track I Status
- Vybion’s Huntington Drug Neutralizes Critical Disease Driver
- Warning after '55% increase in Huntington's disease sufferers'
- Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease
- Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
- WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease
- Wave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington’s Disease Program at CHDI Foundation’s 15th Annual HD Therapeutics Conference
- Well-known author and historian reports on progress in Huntington's therapies
- What Doesn’t Kill You Makes You Stronger
- What Geneticists Think You Should Know
- What matters most to Huntington's disease patients? New survey
- Winning the Wolfson bid: how UCL secured its biggest research grant
- World's top researchers collaborate to diagnose and treat rare genetic diseases
- World-first Huntington's study
- Yale’s partnership against Huntington’s disease: an alumnus reconnects and finds hope as scientists pursue ‘Viagra for the brain’ and other solutions
- Zinc Fingers: A New Tool in the Fight Against Huntington's Disease
- ‘Darkness replaced by hope and light’: taking stock of Huntington’s disease research
Plugin by dagondesign.com
